Travere Therapeutics, Inc.
No SEC Form 4 filings for $TVTX in the last 30 days.
A dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
Simply Wall St discusses Travere Therapeutics (TVTX) Q2 2026 results. Revenue rose to $169.58M from $114.45M, while net loss widened to $34.8M and basic loss per share to $0.37. The company cited record demand for FILSPARI in IgA nephropathy and an early FSGS launch, plus pipeline progress via civorebrutinib in-licensing and HARMONY pegtibatinase.
Travere Therapeutics (TVTX) shares rose more than 13% after hours after results for the quarter ended June 30. Total revenue was $169.58 million, above analysts’ $159.32 million estimate. U.S. net product sales rose to $161.4 million, with FILSPARI at $141.1 million. EPS was a loss of $0.10 versus a $0.23 estimate.
Over the past 7 days, alphai's AI scored 4 news stories mentioning TVTX (Travere Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent TVTX coverage spans mergers & acquisitions, earnings and sector analysis.
TVTX’s move is presented as earnings-related, which can support momentum trades but lacks detail here.
FILSPARI demand is strengthening top-line, but widening losses and cash-burn risk likely keep valuation and near-term sentiment fragile.
The earnings beat and sharp jump in FILSPARI sales are the primary catalyst behind the reported after-hours rally, despite a wider EPS and net loss.
Strong commercial momentum for FILSPARI and updated pipeline milestones (HARMONY Phase 3 topline expected in 2H 2027) support a constructive near-to-medium term risk view, despite higher operating expenses and a larger SG&A base.
Management accounting leadership transition is unlikely to change near-term fundamentals, but it can affect reporting continuity and internal control oversight into the next 10-K.
alphai scores every news story that mentions TVTX with an AI model for sentiment and relevance, and aggregates insider trades from Travere Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
4 min readSimply Wall St discusses Travere Therapeutics (TVTX) Q2 2026 results. Revenue rose to $169.58M from $114.45M, while net loss widened to $34.8M and basic loss per share to $0.37. The company cited record demand for FILSPARI in IgA nephropathy and an early FSGS launch, plus pipeline progress via civorebrutinib in-licensing and HARMONY pegtibatinase.
6 min readTravere Therapeutics (TVTX) shares rose more than 13% after hours after results for the quarter ended June 30. Total revenue was $169.58 million, above analysts’ $159.32 million estimate. U.S. net product sales rose to $161.4 million, with FILSPARI at $141.1 million. EPS was a loss of $0.10 versus a $0.23 estimate.
4 min readTravere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2_8-kxex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2026 Financial Results Strong FSGS launch and continued IgAN growth drive robus
6 min readTravere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. tvtx-20260706 0001438533 false 0001438533 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K ___________________________ Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of
2 min readEverest Medicines (HKEX 1952) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (NASDAQ TVTX) for civorebrutinib (EVER001) in the US and global markets excluding Greater China and parts of East and Southeast Asia. Everest will receive a $112.5m upfront payment, plus up to about $1.03b milestone payments and tiered royalties on sales.
4 min readEverest Medicines (1952.HK) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East and Southeast Asia. Everest will receive $112.5M upfront and up to about $1.03B in milestone payments, plus tiered royalties.
2 min readEverest Medicines (HKEX:1952) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (NASDAQ:TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East/Southeast Asia. Everest will receive $112.5m upfront and up to ~$1.03b in milestone payments, plus tiered royalties on sales.
3 min readEverest Medicines (HKEX:1952) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (NASDAQ:TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East/Southeast Asia. Everest will receive $112.5M upfront, plus up to ~$1.03B in milestone payments and tiered royalties on sales.
4 min readCoughlin Timothy sold 10,000 shares of Travere Therapeutics, Inc. (TVTX) at $50.07 ($0.50M total) on 2026-06-12 under a Rule 10b5-1 trading plan.
1 min read
